455 related articles for article (PubMed ID: 33513818)
1. Blood-Brain Barrier Disruption Increases Amyloid-Related Pathology in TgSwDI Mice.
Abdallah IM; Al-Shami KM; Yang E; Kaddoumi A
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513818
[TBL] [Abstract][Full Text] [Related]
2. Aβ1-42 reduces P-glycoprotein in the blood-brain barrier through RAGE-NF-κB signaling.
Park R; Kook SY; Park JC; Mook-Jung I
Cell Death Dis; 2014 Jun; 5(6):e1299. PubMed ID: 24967961
[TBL] [Abstract][Full Text] [Related]
3. ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides.
Xiong H; Callaghan D; Jones A; Bai J; Rasquinha I; Smith C; Pei K; Walker D; Lue LF; Stanimirovic D; Zhang W
J Neurosci; 2009 Apr; 29(17):5463-75. PubMed ID: 19403814
[TBL] [Abstract][Full Text] [Related]
4. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
Sane R; Agarwal S; Mittapalli RK; Elmquist WF
J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
[TBL] [Abstract][Full Text] [Related]
5. Optimization of dose and route of administration of the P-glycoprotein inhibitor, valspodar (PSC-833) and the P-glycoprotein and breast cancer resistance protein dual-inhibitor, elacridar (GF120918) as dual infusion in rats.
Rowbottom C; Pietrasiewicz A; Tuczewycz T; Grater R; Qiu D; Kapadnis S; Trapa P
Pharmacol Res Perspect; 2021 Apr; 9(2):e00740. PubMed ID: 33660938
[TBL] [Abstract][Full Text] [Related]
6. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.
Agarwal S; Sane R; Gallardo JL; Ohlfest JR; Elmquist WF
J Pharmacol Exp Ther; 2010 Jul; 334(1):147-55. PubMed ID: 20421331
[TBL] [Abstract][Full Text] [Related]
7. Abundance of P-Glycoprotein and Other Drug Transporters at the Human Blood-Brain Barrier in Alzheimer's Disease: A Quantitative Targeted Proteomic Study.
Storelli F; Billington S; Kumar AR; Unadkat JD
Clin Pharmacol Ther; 2021 Mar; 109(3):667-675. PubMed ID: 32885413
[TBL] [Abstract][Full Text] [Related]
8. Aβ₁₋₄₂-RAGE interaction disrupts tight junctions of the blood-brain barrier via Ca²⁺-calcineurin signaling.
Kook SY; Hong HS; Moon M; Ha CM; Chang S; Mook-Jung I
J Neurosci; 2012 Jun; 32(26):8845-54. PubMed ID: 22745485
[TBL] [Abstract][Full Text] [Related]
9. Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents.
Agarwal S; Mittapalli RK; Zellmer DM; Gallardo JL; Donelson R; Seiler C; Decker SA; Santacruz KS; Pokorny JL; Sarkaria JN; Elmquist WF; Ohlfest JR
Mol Cancer Ther; 2012 Oct; 11(10):2183-92. PubMed ID: 22891038
[TBL] [Abstract][Full Text] [Related]
10. Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).
Do TM; Dodacki A; Alata W; Calon F; Nicolic S; Scherrmann JM; Farinotti R; Bourasset F
J Alzheimers Dis; 2016; 49(2):287-300. PubMed ID: 26484906
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Hit Compounds Identified from High-throughput Screening for their Effect on Blood-brain Barrier Integrity and Amyloid-β Clearance: In Vitro and In Vivo Studies.
Elfakhri KH; Duong QV; Langley C; Depaula A; Mousa YM; Lebeouf T; Cain C; Kaddoumi A
Neuroscience; 2018 May; 379():269-280. PubMed ID: 29596966
[TBL] [Abstract][Full Text] [Related]
12. ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier.
Do TM; Noel-Hudson MS; Ribes S; Besengez C; Smirnova M; Cisternino S; Buyse M; Calon F; Chimini G; Chacun H; Scherrmann JM; Farinotti R; Bourasset F
J Alzheimers Dis; 2012; 30(1):155-66. PubMed ID: 22391220
[TBL] [Abstract][Full Text] [Related]
13. Protecting P-glycoprotein at the blood-brain barrier from degradation in an Alzheimer's disease mouse model.
Ding Y; Zhong Y; Baldeshwiler A; Abner EL; Bauer B; Hartz AMS
Fluids Barriers CNS; 2021 Mar; 18(1):10. PubMed ID: 33676539
[TBL] [Abstract][Full Text] [Related]
14. Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Blood-Brain Barrier: A PET Study on Nonhuman Primates.
Tournier N; Goutal S; Auvity S; Traxl A; Mairinger S; Wanek T; Helal OB; Buvat I; Soussan M; Caillé F; Langer O
J Nucl Med; 2017 Jan; 58(1):117-122. PubMed ID: 27493269
[TBL] [Abstract][Full Text] [Related]
15. The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid.
Karbownik A; Sobańska K; Płotek W; Grabowski T; Klupczynska A; Plewa S; Grześkowiak E; Szałek E
Invest New Drugs; 2020 Jun; 38(3):574-583. PubMed ID: 31177402
[TBL] [Abstract][Full Text] [Related]
16. Oleocanthal enhances amyloid-β clearance from the brains of TgSwDI mice and in vitro across a human blood-brain barrier model.
Qosa H; Batarseh YS; Mohyeldin MM; El Sayed KA; Keller JN; Kaddoumi A
ACS Chem Neurosci; 2015 Nov; 6(11):1849-59. PubMed ID: 26348065
[TBL] [Abstract][Full Text] [Related]
17. Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice.
Biali ME; Auvity S; Cisternino S; Smirnova M; Hacker M; Zeitlinger M; Mairinger S; Tournier N; Bauer M; Langer O
Mol Pharm; 2023 Nov; 20(11):5877-5887. PubMed ID: 37883694
[TBL] [Abstract][Full Text] [Related]
18. Local perfusion of capillaries reveals disrupted beta-amyloid homeostasis at the blood-brain barrier in Tg2576 murine Alzheimer's model.
Hanafy AS; Lamprecht A; Dietrich D
Fluids Barriers CNS; 2023 Nov; 20(1):85. PubMed ID: 37993886
[TBL] [Abstract][Full Text] [Related]
19. Physical blood-brain barrier disruption induced by focused ultrasound does not overcome the transporter-mediated efflux of erlotinib.
Goutal S; Gerstenmayer M; Auvity S; Caillé F; Mériaux S; Buvat I; Larrat B; Tournier N
J Control Release; 2018 Dec; 292():210-220. PubMed ID: 30415015
[TBL] [Abstract][Full Text] [Related]
20. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Stundner G; Karch R; Brauner R; Meier M; Ding X; Müller M; Löscher W; Langer O
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):942-53. PubMed ID: 20016890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
